Deciphera Pharmaceuticals (FRA:D05) Purchase Of Business : €0.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Deciphera Pharmaceuticals Purchase Of Business?

Deciphera Pharmaceuticals's purchase of business for the three months ended in Dec. 2023 was €0.0 Mil. It means Deciphera Pharmaceuticals spent €0.0 Mil on purchasing business. Deciphera Pharmaceuticals's purchase of business for the trailing twelve months (TTM) ended in Dec. 2023 was €0.0 Mil.

Compared with last quarter (€0.0 Mil in Sep. 2023 ), Deciphera Pharmaceuticals spent the same money on purchasing business in Dec. 2023 (€0.0 Mil).

Deciphera Pharmaceuticals Purchase Of Business Historical Data

The historical data trend for Deciphera Pharmaceuticals's Purchase Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Deciphera Pharmaceuticals Purchase Of Business Chart

Deciphera Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Purchase Of Business

Get a 7-Day Free Trial

Deciphera Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Purchase Of Business	Get a 7-Day Free Trial															-	-	-	-	-

Deciphera Pharmaceuticals Purchase Of Business Calculation

The amount used to purchase business.

Purchase Of Business for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

Deciphera Pharmaceuticals Purchase Of Business Related Terms

Thank you for viewing the detailed overview of Deciphera Pharmaceuticals's Purchase Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.

Deciphera Pharmaceuticals (FRA:D05) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Deciphera Pharmaceuticals Inc (FRA:D05) » Definitions » Purchase Of Business

Comparable Companies

Traded in Other Exchanges

DCPH:USA

Address

200 Smith Street, Waltham, MA, USA, 02451

Website

https://www.deciphera.com

Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.

Deciphera Pharmaceuticals (FRA:D05) Headlines

No Headlines